Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Trading 12-11 15:49:30 EST

6.43

+0.11

+1.75%

High6.51	Low6.21	Vol264.29K
Open6.31	D1 Closing6.32	Amplitude4.75%
Mkt Cap209.13M	Tradable Cap145.50M	Total Shares32.52M
T/O1.68M	T/O Rate1.17%	Tradable Shares22.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":6.4305,"timestamp":1765486169601,"preClose":6.32,"halted":0,"volume":264291,"delay":0,"floatShares":22626486,"shares":32521599,"eps":-1.786134,"marketStatus":"Trading","change":0.1105,"latestTime":"12-11 15:49:30 EST","open":6.31,"high":6.51,"low":6.21,"amount":1681040.877288,"amplitude":0.047468,"askPrice":6.44,"askSize":237,"bidPrice":6.43,"bidSize":306,"shortable":3,"etf":0,"ttmEps":-1.786134,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":6.32,"preHourTrading":{"tag":"盘前","latestPrice":6.36,"preClose":6.32,"latestTime":"09:10 EST","volume":901,"amount":5733.631531,"timestamp":1765462253088},"postHourTrading":{"tag":"盘后","latestPrice":6.32,"preClose":6.32,"latestTime":"19:57 EST","volume":67741,"amount":428123.08,"timestamp":1765414641151},"volumeRatio":0.423094,"impliedVol":1.0584,"impliedVolPercentile":0.084},"requestUrl":"/m/hq/s/SGMT/tweets","defaultTab":"tweets","newsList":[{"id":"2590058233","title":"BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat","url":"https://stock-news.laohu8.com/highlight/detail?id=2590058233","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590058233?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:43","pubTimestamp":1765370632,"startTime":"0","endTime":"0","summary":"BRIEF-Sagimet’S License Partner Ascletis Announced Acceptance Of New Drug Application For Denifanstat Dec 10 (Reuters) - Sagimet Biosciences Inc SGMT.O:SAGIMET’S LICENSE PARTNER ASCLETIS ANNOUNCED ACC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA3RPNQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2590584346","title":"Sagimet Biosciences Inc - Grants Exclusive License to Denifanstat for China to Ascletis","url":"https://stock-news.laohu8.com/highlight/detail?id=2590584346","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590584346?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:03","pubTimestamp":1765368223,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA3RPNQJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2590581783","title":"Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2590581783","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590581783?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:03","pubTimestamp":1765368223,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA3RPNQJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2590432142","title":"Sagimet Biosciences Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2590432142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590432142?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:05","pubTimestamp":1765314308,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. has approved inducement grants totaling 42,800 stock options for three newly hired employees. The options, to be granted on December 9, 2025, will have an exercise price equal to the closing price of Sagimet's Series A common stock on that date. The options have a ten-year term and will vest over four years: 25% on the one-year anniversary of employment commencement, with the remaining shares vesting monthly over the following 36 months, contingent on continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on December 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLbksC7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","BK4112","LU0314104364.USD","LU2095319765.USD","SG9999014005.SGD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","SG9999014039.USD","LU2210149790.SGD","SGMT","LU2210150020.SGD","SG9999014013.SGD","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2590322888","title":"Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590322888","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590322888?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:05","pubTimestamp":1765314300,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Dec.  09, 2025  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/09/3202776/0/en/Sagimet-Biosciences-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2587573606","title":"Buy Rating for Sagimet Biosciences: Promising Pipeline Developments and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2587573606","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587573606?lang=en_us&edition=fundamental","pubTime":"2025-11-29 00:05","pubTimestamp":1764345930,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on SGMT stock, giving a Buy rating on November 25. Debanjana Chatterj...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-sagimet-biosciences-promising-pipeline-developments-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-sagimet-biosciences-promising-pipeline-developments-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2585121708","title":"Executive Chairman George Kemble Reports Sale of Sagimet Biosciences Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585121708","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585121708?lang=en_us&edition=fundamental","pubTime":"2025-11-22 07:13","pubTimestamp":1763766829,"startTime":"0","endTime":"0","summary":"George Kemble, Executive Chairman of Sagimet Biosciences Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL2QqQ7p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Executive Chairman George Kemble Reports Sale of Sagimet Biosciences Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2584413629","title":"Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2584413629","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584413629?lang=en_us&edition=fundamental","pubTime":"2025-11-20 20:00","pubTimestamp":1763640000,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Nov.  20, 2025  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3191757/0/en/Sagimet-Biosciences-to-Participate-in-the-8th-Annual-Evercore-ISI-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","XLV","BK4137","SGMT","LU0128526141.USD","LABU","BK4588","LU0029874061.USD","BK4585","XBI","BK4581","BK4139"],"gpt_icon":0},{"id":"2583500346","title":"Sagimet Biosciences Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2583500346","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583500346?lang=en_us&edition=fundamental","pubTime":"2025-11-14 23:38","pubTimestamp":1763134680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2025 10:38 ET (15:38 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2583050844","title":"Canaccord Genuity Remains a Buy on Sagimet Biosciences, Inc. Class A (SGMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583050844","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583050844?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:56","pubTimestamp":1763121364,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Edward Nash maintained a Buy rating on Sagimet Biosciences, Inc. Class A today and set a price target of $28.00. Nash cov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-sagimet-biosciences-inc-class-a-sgmt-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-remains-a-buy-on-sagimet-biosciences-inc-class-a-sgmt-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2583567577","title":"Sagimet Biosciences price target raised to $35 from $33 at Citizens JMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2583567577","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583567577?lang=en_us&edition=fundamental","pubTime":"2025-11-14 18:50","pubTimestamp":1763117424,"startTime":"0","endTime":"0","summary":"Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on Sagimet Biosciences (SGMT) to $35 from $33 and keeps an Outperform rating ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-35-from-33-at-citizens-jmp-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-35-from-33-at-citizens-jmp-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","SGMT"],"gpt_icon":0},{"id":"2583157955","title":"Optimistic Buy Rating for Sagimet Biosciences Driven by Promising Clinical Progress and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2583157955","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583157955?lang=en_us&edition=fundamental","pubTime":"2025-11-14 03:05","pubTimestamp":1763060732,"startTime":"0","endTime":"0","summary":"Analyst Yun Zhong of Wedbush reiterated a Buy rating on Sagimet Biosciences, Inc. Class A, retaining the price target of $28.00. Yun Zhong has give...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-sagimet-biosciences-driven-by-promising-clinical-progress-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-sagimet-biosciences-driven-by-promising-clinical-progress-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","SGMT"],"gpt_icon":0},{"id":"2583850560","title":"Sagimet Biosciences Q3 net loss narrows as costs drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2583850560","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583850560?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:41","pubTimestamp":1763037670,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Q3 net loss narrows as costs dropOverviewSagimet reports Q3 net loss of $12.9 mlnR&D expenses for Q3 2025 decreased to $9.7 mln from $12.7 mln in Q3 2024Cash and equivalents stand ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0HU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT"],"gpt_icon":0},{"id":"2583567230","title":"Sagimet Biosciences reports third quarter 2025 financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583567230","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583567230?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:37","pubTimestamp":1763037432,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. reported cash, cash equivalents, and marketable securities of $125.5 million as of September 30, 2025. Research and development expenses for the third quarter of 2025 were $9.7 million, compared to $12.7 million for the same period in 2024. For the nine months ended September 30, 2025, research and development expenses totaled $32.3 million, up from $24.2 million in the prior year period. During the period, Sagimet initiated a Phase 1 clinical trial of FASN inhibitor TVB-3567 for acne and continued a Phase 1 trial evaluating the combination of denifanstat and resmetirom, with data readouts expected in the first half of 2026. Ascletis, the company's license partner in China, completed a pre-NDA consultation and plans to submit an NDA for denifanstat for moderate-to-severe acne vulgaris.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDLbxyD7w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2583674775","title":"Sagimet Biosciences Q3 EPS $(0.40) Beats $(0.42) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583674775","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583674775?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:36","pubTimestamp":1763037367,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 5.44 percent. This is a 11.11 percent increase over losses of $(0.45) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48830610/sagimet-biosciences-q3-eps-0-40-beats-0-42-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"gpt_icon":0},{"id":"2583677475","title":"Sagimet Biosciences reports Q3 EPS (40c), consensus (39c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583677475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583677475?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:35","pubTimestamp":1763037339,"startTime":"0","endTime":"0","summary":"“This is a dynamic period for Sagimet as we explore the therapeutic potential of FASN inhibition across different indications,” said David Happel, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-reports-q3-eps-40c-consensus-39c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-reports-q3-eps-40c-consensus-39c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"gpt_icon":0},{"id":"2583627567","title":"Sagimet Biosciences Launches Phase 1 Trial of Denifanstat and Resmetirom Combination for MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2583627567","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583627567?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037025,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. has announced the ongoing Phase 1 clinical trial evaluating the pharmacokinetics  and tolerability of a combination of denifanstat and resmetirom, with data readout expected in the first half of 2026. Additionally, Sagimet has initiated a first-in-human Phase 1 clinical trial of its second FASN inhibitor, TVB-3567, aimed at developing an acne indication. The company anticipates starting a Phase 2 clinical trial in moderate to severe acne patients in 2026, subject to regulatory consultation, following completion of the ongoing Phase 1 study of TVB-3567. No results from these studies have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content use","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL60M32m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4139","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","SGMT","BK4585","BK4588","NDAQ","LU2210150020.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2583640567","title":"Press Release: Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583640567","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583640567?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037000,"startTime":"0","endTime":"0","summary":"Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026. First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing. Ascletis announced completion of its pre-NDA consultation with China's NMPA and plans to submit an NDA for denifanstat in China for treatment of moderate-to-severe acne vulgaris. \"This is a dynamic period for Sagimet as we explore the therapeutic potential of FASN inhibition across different indications,\" said David Happel, Chief Executive Officer of Sagimet. \"As part of our MASH development program targeting cirrhosis of the liver, we have initiated a Phase 1 PK trial evaluating the compatibility of a once-daily combination of denifanstat and resmetirom. We plan to use this data, if positive, to advance the combination to proof-of-concept studies in MASH patients with F4 fibrosis. Additionally, we initiated a Phase 1 clinical trial of our second FASN inhibitor, TVB-3567, for develo","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMT","00511","BK4085","R","BK4232","PK","BK4181","BK4218","BK4022","DDI","BK1145"],"gpt_icon":0},{"id":"2582879136","title":"Sagimet Biosciences presents two denifanstat posters at AASLD","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879136?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:55","pubTimestamp":1762779308,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (SGMT) announced the presentation of two posters at the American Association for the Study of Liver Disease, AASLD – The Liver ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-presents-two-denifanstat-posters-at-aasld-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-presents-two-denifanstat-posters-at-aasld-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"gpt_icon":0},{"id":"2582873953","title":"Sagimet Biosciences Reports Denifanstat Significantly Improves Advanced MASH Fibrosis in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873953","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873953?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:02","pubTimestamp":1762776160,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences Inc. has announced the presentation of two posters at the American Association for the Study of Liver Disease  - The Liver Meeting 2025, held from November 7-11, 2025, in Washington, DC. The presentations detailed results from secondary analyses of the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in patients with metabolic dysfunction-associated steatohepatitis  and advanced fibrosis. One poster, presented by Dr. Rohit Loomba, reported that denifanstat treatment led to significant improvements in liver fibrosis, including a ≥2-stage improvement in fibrosis in F3 MASH patients and improved liver fibrosis and biomarkers in patients identified as qFibrosis stage 4  by AI-based digital pathology. In the qF4 subgroup, 85% of denifanstat-treated patients experienced at least a 1-stage regression in fibrosis compared to 33% in the placebo group. A second poster, presented by Dr. Vlad Ratziu, used spatial computational histology to stratify responders to denif","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7BcPZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","LU2095319765.USD","NDAQ","BK4139","IE00BKPKM429.USD","SGMT","BK4588","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","LU0314104364.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.2413},{"period":"3month","weight":-0.1023},{"period":"6month","weight":-0.2358},{"period":"1year","weight":0.2924},{"period":"ytd","weight":0.4044}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction